Literature DB >> 22805624

Circulating levels of adiponectin, orexin-A, ghrelin and the antioxidant paraoxonase-1 in metabolic syndrome.

O Tabak1, R Gelişgen, H Cicekçi, E Senateş, F Erdenen, C Müderrisoğlu, H Aral, H Uzun.   

Abstract

AIM: Metabolic syndrome (MS) is a disorder consisting of various abnormalities such as dyslipidemia, obesity, hypertension and hyperglycemia. Over the past two decades, the prevalence of MS has greatly increased, and it has become a global health problem. We measured and compared plasma concentrations of adiponectin, orexin-A, ghrelin and the antioxidant paraoxonase-1 (PON1) between patients with metabolic syndrome (MS) and healthy controls.
METHODS: A total of 87 patients (46 women, 41 men) with MS and 40 healthy controls (21 women, 19 men) with a BMI less than 25 kg/m2 were enrolled in the study. The plasma concentrations of the adiponectin, orexin-A, ghrelin and PON1 were measured by ELISA.
RESULTS: Plasma concentrations of Orexin-A were significantly higher in patients with MS than controls (P<0.001). However, plasma concentrations of adiponectin, ghrelin and PON1 were significantly lower in patients with MS compared to controls (P<0.001, P<0.001 and P<0.001, respectively).
CONCLUSION: Our data confirmed the previous findings that plasma concentrations of orexin-A is higher than controls, however plasma concentrations of PON1, ghrelin and adiponectin are lower compared to controls.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22805624

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  5 in total

1.  Associations of plasma hypocretin-1 with metabolic and reproductive health: Two systematic reviews of clinical studies.

Authors:  Galit L Dunietz; Giancarlo Vanini; Carol Shannon; Louise M O'Brien; Ronald D Chervin
Journal:  Sleep Med Rev       Date:  2020-03-17       Impact factor: 11.609

2.  Soluble Lectin-Like Oxidized LDL Receptor 1 as a Possible Mediator of Endothelial Dysfunction in Patients With Metabolic Syndrome.

Authors:  S Civelek; M Kutnu; H Uzun; F Erdenen; E Altunoglu; G Andican; A Seven; A O Sahin; G Burcak
Journal:  J Clin Lab Anal       Date:  2014-05-05       Impact factor: 2.352

3.  Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity.

Authors:  Chiara Cristina Bortolasci; Heber Odebrecht Vargas; André Souza-Nogueira; Estefania Gastaldello Moreira; Sandra Odebrecht Vargas Nunes; Michael Berk; Seetal Dodd; Décio Sabbatini Barbosa; Michael Maes
Journal:  Redox Rep       Date:  2014-07-18       Impact factor: 4.412

4.  Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report.

Authors:  Antonio Bustos; Pablo Selvi Sabater; María Benlloch; Eraci Drehmer; María Mar López-Rodríguez; Felix Platero; Jose Luis Platero; Jesús Escribá-Alepuz; Jose Enrique de la Rubia Ortí
Journal:  Medicina (Kaunas)       Date:  2021-01-24       Impact factor: 2.430

5.  Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics.

Authors:  Po-Yu Chen; Chun-Hsin Chen; Chin-Kuo Chang; Chung-Feng Kao; Mong-Liang Lu; Shih-Ku Lin; Ming-Chyi Huang; Ling-Ling Hwang; Valeria Mondelli
Journal:  Int J Neuropsychopharmacol       Date:  2019-01-01       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.